China vs Indonesia: The number of people with susceptibility test result for rifampicin
China
237,238
in 2021
Indonesia
144,511
in 2021
China rank
2nd
Indonesia rank
3rd
The number of people with susceptibility test result for rifampicin over time
- China
- Indonesia
How they compare
China currently reports 237,238 against 144,511 in Indonesia, a difference of 92,727.
That makes China's figure about 1.6 times Indonesia's.
Across all 5 years both countries report, China has been ahead every year.
China ranks 2nd and Indonesia ranks 3rd of 155 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 156,421 | 71,327 | 85,095 | China |
| 2020s | 242,912 | 121,178 | 121,734 | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or Indonesia?
- China, at 237,238 against 144,511 in Indonesia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and Indonesia?
- 92,727, with China ahead.
- How many years of comparable data are there for China and Indonesia?
- 5 years are reported by both, from 2017 to 2021.
- How do China and Indonesia rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 2nd and Indonesia ranks 3rd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.